This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
Voluntarily sign the informed consent form (ICF);
ECOG 0-1;
Survival duration more than 3 months;
Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and cannot receive curative concurrent/sequential chemoradiotherapy;
Histologically or cytologically confirmed presence of small cell carcinoma components;
Prior treatment with docetaxel;
Symptomatic central nervous system (CNS) metastases;
Received the last dose of prior systemic anti-tumor therapy within 4 weeks before the first dose of study drug;